Hepatitis A Therapeutics Market Size, Share, and Industry Analysis, By Drug Class (Antiemetics, Antipyretics, and Others), By Route of Administration (Oral and Parenteral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies & Drug Stores, and Online Pharmacies), and Regional Forecast, 2026-2034

The hepatitis A therapeutics market is experiencing significant growth driven by increasing awareness, particularly in developing regions with inadequate sanitation. Hepatitis A typically occurs in vulnerable populations, which creates a need for effective treatment options and drives the market growth. Additionally, a rise in research activities for the development of treatment options for hepatitis A support the market growth.

Hepatitis A is a liver infection caused by the hepatitis A virus (HAV). It is commonly transmitted through contaminated food & water, or through close contact with an infected individual. Most of the hepatitis A cases resolve on their own without long-term liver damage.

• For instance, according to the data published by the National Center for Biotechnology Information, in April 2023, hepatitis A is a common infection in low-income countries and affects millions of people worldwide.

Hepatitis A Therapeutics Market Driver

Rise in Incidence of Hepatitis A Drives Market Growth

The rise in incidence of hepatitis A due to poor hygiene and sanitation is expected to drive the market growth during the forecast period. An increase in global travel, especially to regions with poor sanitation, is expected to increase the risk of disease transmission and increase the demand for hepatitis A therapeutics. Additionally, various diseases and conditions can lead to liver inflammation, which is expected to cause hepatitis A and further boost the market growth.

• For instance, according to the data published by the National Library of Medicine, in October 2023, individuals with HIV, hepatitis B, and hepatitis C are at a higher risk of experiencing more severe hepatitis A infections. These associated conditions increase the incidence of hepatitis A and support the market growth.

Incidence of Hepatitis A (in million), By Country, 2019

According to the data published by the National Center for Biotechnology Information, in August 2021, the number of hepatitis A incidences in India was 30.4 million, and in China, it was 19.4 million. These cases are approximately one-third of global hepatitis A incidence (158.94 million) in 2019.

Hepatitis A Therapeutics Market Restraint

Lack of a Specific Curative Therapy is Expected to Hinder Market Growth

The absence of a specific curative therapy for hepatitis A is expected to hinder the growth of the hepatitis A therapeutics market, as it is a self-limiting infection that the body's immune system can clear on its own. Most individuals recover within a few weeks without any specific medical intervention, but severe or pediatric patient needs medical attention. Also, some of the currently used medicines, such as paracetamol, have some side effects, which are expected to limit the market growth.

• For instance, according to the data published by the World Health Organization (WHO), in February 2025, there is no specific antiviral medication to treat hepatitis A, thus, recovery from this infection is also slow.

Hepatitis A Therapeutics Market Opportunity

Development of Effective Treatment Options Expected to Offer Prominent Growth Opportunities in Future

The development of effective hepatitis A treatments, such as antiviral therapies, is expected to offer a prominent growth opportunity in the hepatitis A therapeutics market. The increasing focus on research activities for developing antiviral drugs that enhance the immune system and accelerate recovery is expected to provide market growth opportunities during the forecast period.

• For instance, according to the data published by the National Center for Biotechnology Information, in April 2023, to study the interferon effect, three patients with hepatitis A were treated with interferon-beta, which resulted in an improvement in liver function and survival. These type of development studies provides market growth opportunities in the future.

Key Insights

The report covers the following key insights:

• Incidence of Hepatitis A Infections, By Key Countries/Regions, 2024
• Pipeline Analysis, By Key Players
• Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
• Overview: Current Therapies for Hepatitis A Infection

Segmentation

Analysis by Drug Class

By drug class, the market is divided into antiemetics, antipyretics, and others.

The antiemetics segment accounted for a significant revenue in the market. This growth is due to its effectiveness in managing the common symptoms of hepatitis A, such as nausea and vomiting. There is no specific antiviral treatment for hepatitis A, thus, antiemetics play an important role in the supportive care, which is expected to drive the segment growth in this market.

• For instance, antiemetics, such as metoclopramide, are used as supportive care in the treatment of hepatitis A.

Analysis by Route of Administration 

By route of administration, the market is divided into oral and parenteral.

The oral segment held a significant share of the Hepatitis A market in 2024. This is due to its ease of administration and high patient preference. The majority of hepatitis A cases are treated with oral medications, resulting in high patient compliance, which increases the product adoption rate and drives the segment growth.

• For instance, Metoclopramide is an oral antiemetic used to relieve nausea and vomiting by increasing stomach and intestinal contractions. It is suitable for patients with hepatitis A as it is minimally metabolized by the liver.

Analysis by Distribution Channel

By distribution channel, the market is divided into hospital pharmacies, retail pharmacies & drug stores, and online pharmacies.

Hospital pharmacies held a considerable market share in 2024. This is primarily due to the higher volume of patients being diagnosed and treated for hepatitis in hospital settings, which increases the prescriptions of medications in these institutions. Additionally, it’s an acute disease, but sometimes leads to severe complications and requires hospitalization, which supports the hospital pharmacies segment growth. 

Regional Analysis

By region, the market is divided into North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America.

Request for Customization   to gain extensive market insights.

North America accounted for a significant share of the global hepatitis A therapeutics market in 2024. The rise in incidence of hepatitis A infections propels the market growth during the forecast period. Furthermore, high awareness and strong presence of research institutes and pharmaceutical industries in this region support the market growth.

• For instance, according to data published by the Centers for Disease Control and Prevention, in August 2023, the number of cases of Hepatitis A in 2021 was 4 times higher than in 2015.

Europe held a substantial share of the hepatitis A therapeutics market. The growth of the region can be attributed to a rise in cases of hepatitis A, especially among migrant populations. Additionally, a rise in awareness and testing access is expected to drive the market growth in this region.

Asia Pacific is the fastest-growing region during the forecasting years. The rise in the geriatric population has a high chance of getting infected. This is due to they have weakened immune systems, which is expected to increase the patient population, and further drive the market growth in this region.

Key Players Covered

The global hepatitis A therapeutics market represents a fragmented structure with few key players. The report includes the profiles of the following key players:

• ANI Pharmaceuticals, Inc. (U.S.)
• Takeda Pharmaceuticals, Inc. (Japan)
• Mallinckrodt (Ireland)
• Teva Pharmaceuticals, Inc. (Israel)
• AMBICA PHARMA (India)
• PHARMA CURE LABORATORIES (India)

Key Industry Developments

• In October 2023, the Japan Agency for Medical Research and Development (AMED) Hepatitis A and E viruses (HAV and HEV) Study Group worked on a project and created a document titled “Recent advances in hepatitis A virus (HAV) research and clinical practice guidelines for HAV infection in Japan”.
• In April 2023, new research suggested that corticosteroids accounted for a valuable complementary treatment for acute Hepatitis A, particularly in children experiencing severe forms of the illness. The findings, based on a study conducted by Zakaria et al